Cargando…

Plasminogen Deficiency and Amiloride Mitigate Angiotensin II–Induced Hypertension in Type 1 Diabetic Mice Suggesting Effects Through the Epithelial Sodium Channel

BACKGROUND: Diabetic nephropathy is a common diabetes mellitus complication associated with hypertension, proteinuria, and excretion of urinary plasmin that activates the epithelial sodium channel, ENaC, in vitro. Here we hypothesized that the deletion of plasminogen and amiloride treatment protect...

Descripción completa

Detalles Bibliográficos
Autores principales: Andersen, Henrik, Hansen, Maria Høj, Buhl, Kristian B., Stæhr, Mette, Friis, Ulla G., Enggaard, Camilla, Supramaniyam, Shanya, Lund, Ida K., Svenningsen, Per, Hansen, Pernille B. L., Jensen, Boye L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7763785/
https://www.ncbi.nlm.nih.gov/pubmed/33215566
http://dx.doi.org/10.1161/JAHA.120.016387
_version_ 1783628100837310464
author Andersen, Henrik
Hansen, Maria Høj
Buhl, Kristian B.
Stæhr, Mette
Friis, Ulla G.
Enggaard, Camilla
Supramaniyam, Shanya
Lund, Ida K.
Svenningsen, Per
Hansen, Pernille B. L.
Jensen, Boye L.
author_facet Andersen, Henrik
Hansen, Maria Høj
Buhl, Kristian B.
Stæhr, Mette
Friis, Ulla G.
Enggaard, Camilla
Supramaniyam, Shanya
Lund, Ida K.
Svenningsen, Per
Hansen, Pernille B. L.
Jensen, Boye L.
author_sort Andersen, Henrik
collection PubMed
description BACKGROUND: Diabetic nephropathy is a common diabetes mellitus complication associated with hypertension, proteinuria, and excretion of urinary plasmin that activates the epithelial sodium channel, ENaC, in vitro. Here we hypothesized that the deletion of plasminogen and amiloride treatment protect against hypertension in diabetes mellitus. METHODS AND RESULTS: Male plasminogen knockout (plasminogen‐deficient [Plg(−/−)]) and wild‐type mice were rendered diabetic with streptozotocin. Arterial blood pressure was recorded continuously by indwelling catheters before and during 10 days of angiotensin II infusion (ANGII; 30–60 ng/kg per minute). The effect of amiloride infusion (2 mg/kg per day, 4 days) was tested in wild‐type, diabetic ANGII‐treated mice. Streptozotocin increased plasma and urine glucose concentrations and 24‐hour urine albumin and plasminogen excretion. Diabetic Plg(−/−) mice displayed larger baseline albuminuria and absence of urine plasminogen. Baseline mean arterial blood pressure did not differ between groups. Although ANGII elevated blood pressure in wild‐type, diabetic wild‐type, and Plg(−/−) control mice, ANGII did not change blood pressure in diabetic Plg(−/−) mice. Compared with ANGII infusion alone, wild‐type ANGII‐infused diabetic mice showed blood pressure reduction upon amiloride treatment. There was no difference in plasma renin, ANGII, aldosterone, tissue prorenin receptor, renal inflammation, and fibrosis between groups. Urine from wild‐type mice evoked larger amiloride‐sensitive current than urine from Plg(−/−) mice with or without diabetes mellitus. Full‐length γ‐ENaC and α‐ENaC subunit abundances were not changed in kidney homogenates, but the 70 kDa γ‐ENaC cleavage product was increased in diabetic versus nondiabetic mice. CONCLUSIONS: Plasmin promotes hypertension in diabetes mellitus with albuminuria likely through the epithelial sodium channel.
format Online
Article
Text
id pubmed-7763785
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-77637852020-12-28 Plasminogen Deficiency and Amiloride Mitigate Angiotensin II–Induced Hypertension in Type 1 Diabetic Mice Suggesting Effects Through the Epithelial Sodium Channel Andersen, Henrik Hansen, Maria Høj Buhl, Kristian B. Stæhr, Mette Friis, Ulla G. Enggaard, Camilla Supramaniyam, Shanya Lund, Ida K. Svenningsen, Per Hansen, Pernille B. L. Jensen, Boye L. J Am Heart Assoc Original Research BACKGROUND: Diabetic nephropathy is a common diabetes mellitus complication associated with hypertension, proteinuria, and excretion of urinary plasmin that activates the epithelial sodium channel, ENaC, in vitro. Here we hypothesized that the deletion of plasminogen and amiloride treatment protect against hypertension in diabetes mellitus. METHODS AND RESULTS: Male plasminogen knockout (plasminogen‐deficient [Plg(−/−)]) and wild‐type mice were rendered diabetic with streptozotocin. Arterial blood pressure was recorded continuously by indwelling catheters before and during 10 days of angiotensin II infusion (ANGII; 30–60 ng/kg per minute). The effect of amiloride infusion (2 mg/kg per day, 4 days) was tested in wild‐type, diabetic ANGII‐treated mice. Streptozotocin increased plasma and urine glucose concentrations and 24‐hour urine albumin and plasminogen excretion. Diabetic Plg(−/−) mice displayed larger baseline albuminuria and absence of urine plasminogen. Baseline mean arterial blood pressure did not differ between groups. Although ANGII elevated blood pressure in wild‐type, diabetic wild‐type, and Plg(−/−) control mice, ANGII did not change blood pressure in diabetic Plg(−/−) mice. Compared with ANGII infusion alone, wild‐type ANGII‐infused diabetic mice showed blood pressure reduction upon amiloride treatment. There was no difference in plasma renin, ANGII, aldosterone, tissue prorenin receptor, renal inflammation, and fibrosis between groups. Urine from wild‐type mice evoked larger amiloride‐sensitive current than urine from Plg(−/−) mice with or without diabetes mellitus. Full‐length γ‐ENaC and α‐ENaC subunit abundances were not changed in kidney homogenates, but the 70 kDa γ‐ENaC cleavage product was increased in diabetic versus nondiabetic mice. CONCLUSIONS: Plasmin promotes hypertension in diabetes mellitus with albuminuria likely through the epithelial sodium channel. John Wiley and Sons Inc. 2020-11-20 /pmc/articles/PMC7763785/ /pubmed/33215566 http://dx.doi.org/10.1161/JAHA.120.016387 Text en © 2020 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Research
Andersen, Henrik
Hansen, Maria Høj
Buhl, Kristian B.
Stæhr, Mette
Friis, Ulla G.
Enggaard, Camilla
Supramaniyam, Shanya
Lund, Ida K.
Svenningsen, Per
Hansen, Pernille B. L.
Jensen, Boye L.
Plasminogen Deficiency and Amiloride Mitigate Angiotensin II–Induced Hypertension in Type 1 Diabetic Mice Suggesting Effects Through the Epithelial Sodium Channel
title Plasminogen Deficiency and Amiloride Mitigate Angiotensin II–Induced Hypertension in Type 1 Diabetic Mice Suggesting Effects Through the Epithelial Sodium Channel
title_full Plasminogen Deficiency and Amiloride Mitigate Angiotensin II–Induced Hypertension in Type 1 Diabetic Mice Suggesting Effects Through the Epithelial Sodium Channel
title_fullStr Plasminogen Deficiency and Amiloride Mitigate Angiotensin II–Induced Hypertension in Type 1 Diabetic Mice Suggesting Effects Through the Epithelial Sodium Channel
title_full_unstemmed Plasminogen Deficiency and Amiloride Mitigate Angiotensin II–Induced Hypertension in Type 1 Diabetic Mice Suggesting Effects Through the Epithelial Sodium Channel
title_short Plasminogen Deficiency and Amiloride Mitigate Angiotensin II–Induced Hypertension in Type 1 Diabetic Mice Suggesting Effects Through the Epithelial Sodium Channel
title_sort plasminogen deficiency and amiloride mitigate angiotensin ii–induced hypertension in type 1 diabetic mice suggesting effects through the epithelial sodium channel
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7763785/
https://www.ncbi.nlm.nih.gov/pubmed/33215566
http://dx.doi.org/10.1161/JAHA.120.016387
work_keys_str_mv AT andersenhenrik plasminogendeficiencyandamiloridemitigateangiotensiniiinducedhypertensionintype1diabeticmicesuggestingeffectsthroughtheepithelialsodiumchannel
AT hansenmariahøj plasminogendeficiencyandamiloridemitigateangiotensiniiinducedhypertensionintype1diabeticmicesuggestingeffectsthroughtheepithelialsodiumchannel
AT buhlkristianb plasminogendeficiencyandamiloridemitigateangiotensiniiinducedhypertensionintype1diabeticmicesuggestingeffectsthroughtheepithelialsodiumchannel
AT stæhrmette plasminogendeficiencyandamiloridemitigateangiotensiniiinducedhypertensionintype1diabeticmicesuggestingeffectsthroughtheepithelialsodiumchannel
AT friisullag plasminogendeficiencyandamiloridemitigateangiotensiniiinducedhypertensionintype1diabeticmicesuggestingeffectsthroughtheepithelialsodiumchannel
AT enggaardcamilla plasminogendeficiencyandamiloridemitigateangiotensiniiinducedhypertensionintype1diabeticmicesuggestingeffectsthroughtheepithelialsodiumchannel
AT supramaniyamshanya plasminogendeficiencyandamiloridemitigateangiotensiniiinducedhypertensionintype1diabeticmicesuggestingeffectsthroughtheepithelialsodiumchannel
AT lundidak plasminogendeficiencyandamiloridemitigateangiotensiniiinducedhypertensionintype1diabeticmicesuggestingeffectsthroughtheepithelialsodiumchannel
AT svenningsenper plasminogendeficiencyandamiloridemitigateangiotensiniiinducedhypertensionintype1diabeticmicesuggestingeffectsthroughtheepithelialsodiumchannel
AT hansenpernillebl plasminogendeficiencyandamiloridemitigateangiotensiniiinducedhypertensionintype1diabeticmicesuggestingeffectsthroughtheepithelialsodiumchannel
AT jensenboyel plasminogendeficiencyandamiloridemitigateangiotensiniiinducedhypertensionintype1diabeticmicesuggestingeffectsthroughtheepithelialsodiumchannel